– Highly Complementary Companies to Advance Therapies to Address Unmet Patient Needs
– Respective Generics Businesses and Endo’s Sterile Injectables Business to be Combined and Spun Off as an Independent Company with Target Date in the Fourth Quarter of 2025
– New York Stock Exchange (NYSE) Listing of Branded Company Following Spin-off

“We are excited to pursue a promising new future for all the stakeholders of Mallinckrodt and Endo,” said Siggi Olafsson, President and Chief Executive Officer of the combined company. “We commend the employees of both companies for the extraordinary effort required to achieve this milestone. Today we bring together two highly complementary companies with durable, on-market products in our branded portfolio and best-in-class capabilities across the value chain in our generics and sterile injectables business, which we call Par Health. We have a strong balance sheet and meaningful financial flexibility to invest in innovation and business development to drive growth. As a company deeply committed to operating with integrity and purpose, we are focused on delivering significant value to shareholders and employees for the ultimate benefit of the patients we serve.” Read More >